IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
IceCure Medical is expanding its U.S. sales and marketing teams in key territories including New York, Southern California, and the Midwest to address surging demand for its ProSense cryoablation system. The expansion follows a reported 70% growth in the active U.S. commercial install base for breast cancer cryoablation, driven by FDA marketing authorization received in October 2025.
Key figures
- Us install base growth
- 70%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.